iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, such as advanced image analysis and workflow solutions in breast imaging, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD and density assessment analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, the company's digital mammography CAD products comprise magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses through sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. iCAD, Inc. has a strategic partnership agreement with Invivo Corp. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorComputer and Technology
Phone603-882-5200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$25.62 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/13/2019 (Estimated)
OptionableOptionable
iCAD (NASDAQ:ICAD) Frequently Asked Questions
What is iCAD's stock symbol?
iCAD trades on the NASDAQ under the ticker symbol "ICAD."
How were iCAD's earnings last quarter?
iCAD Inc (NASDAQ:ICAD) released its earnings results on Monday, March, 18th. The technology company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. The technology company had revenue of $6.95 million for the quarter, compared to the consensus estimate of $6.55 million. iCAD had a negative return on equity of 59.30% and a negative net margin of 35.19%. View iCAD's Earnings History.
When is iCAD's next earnings date?
Has iCAD been receiving favorable news coverage?
News articles about ICAD stock have trended positive on Monday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. iCAD earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned headlines about the technology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near future.
Who are some of iCAD's key competitors?
Some companies that are related to iCAD include SeaSpine (SPNE), Westaim (WEDXF), Neuronetics (STIM), Apyx Medical (APYX), Cytosorbents (CTSO), Nuvectra (NVTR), Liquidia Technologies (LQDA), T2 Biosystems (TTOO), RenovaCare (RCAR), Sensus Healthcare (SRTS), Alphatec (ATEC), STRATA Skin Sciences (SSKN), Apollo Endosurgery (APEN), CAS Medical Systems (CASM) and Endologix (ELGX).
What other stocks do shareholders of iCAD own?
Who are iCAD's key executives?
iCAD's management team includes the folowing people:
- Ms. Stacey M. Stevens, Exec. VP and Chief Strategy & Commercial Officer (Age 51)
- Mr. Michael S. Klein, Exec. Chairman & CEO (Age 65)
- Mr. R. Scott Areglado, VP, Corp. Controller & Interim CFO
- Ms. Annette L. Heroux, VP of Admin. (Age 62)
- Mr. Jonathan Go, Sr. VP of R&D (Age 56)
Who are iCAD's major shareholders?
iCAD's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Advisor Group Inc. (0.13%), FNY Investment Advisers LLC (0.12%), Columbia Pacific Advisors LLC (0.12%) and IHT Wealth Management LLC (0.07%). View Institutional Ownership Trends for iCAD.
Which institutional investors are buying iCAD stock?
ICAD stock was purchased by a variety of institutional investors in the last quarter, including Advisor Group Inc., FNY Investment Advisers LLC, Columbia Pacific Advisors LLC and IHT Wealth Management LLC. View Insider Buying and Selling for iCAD.
How do I buy shares of iCAD?
Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is iCAD's stock price today?
One share of ICAD stock can currently be purchased for approximately $4.06.
How big of a company is iCAD?
iCAD has a market capitalization of $70.04 million and generates $25.62 million in revenue each year. The technology company earns $-9,020,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis.
What is iCAD's official website?
How can I contact iCAD?
iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company can be reached via phone at 603-882-5200 or via email at [email protected]
MarketBeat Community Rating for iCAD (NASDAQ ICAD)
MarketBeat's community ratings are surveys of what our community members think about iCAD and other stocks. Vote "Outperform" if you believe ICAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
